Technical Analysis for MGNX - MacroGenics, Inc.

Grade Last Price % Change Price Change
D 14.37 -8.47% -1.33
MGNX closed down 8.47 percent on Thursday, April 25, 2024, on 78 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 7
*** please verify all earnings dates ***
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -8.47%
Wide Bands Range Expansion -8.47%
20 DMA Resistance Bearish -11.46%
Wide Bands Range Expansion -11.46%
MACD Bearish Centerline Cross Bearish -6.75%
Wide Bands Range Expansion -6.75%

   Recent Intraday Alerts

Alert Time
Down 1 ATR about 16 hours ago
60 Minute Opening Range Breakdown about 17 hours ago
Gapped Down (Full) about 18 hours ago
Down 5% about 18 hours ago
Down 3% about 18 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

MacroGenics, Inc. Description

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Immune System Antibodies Autoimmune Disease Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Antibody Novel Cancer

Is MGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.88
52 Week Low 4.29
Average Volume 1,539,867
200-Day Moving Average 9.76
50-Day Moving Average 16.78
20-Day Moving Average 16.28
10-Day Moving Average 16.07
Average True Range 1.17
RSI (14) 38.27
ADX 19.0
+DI 23.06
-DI 30.19
Chandelier Exit (Long, 3 ATRs) 16.03
Chandelier Exit (Short, 3 ATRs) 16.33
Upper Bollinger Bands 19.54
Lower Bollinger Band 13.02
Percent B (%b) 0.21
BandWidth 40.06
MACD Line -0.24
MACD Signal Line -0.01
MACD Histogram -0.2281
Fundamentals Value
Market Cap 891.36 Million
Num Shares 62 Million
EPS 0.81
Price-to-Earnings (P/E) Ratio 17.74
Price-to-Sales 9.37
Price-to-Book 5.54
PEG Ratio 0.01
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.56
Resistance 3 (R3) 16.72 16.16 16.20
Resistance 2 (R2) 16.16 15.60 16.08 16.07
Resistance 1 (R1) 15.26 15.25 14.98 15.10 15.95
Pivot Point 14.70 14.70 14.56 14.62 14.70
Support 1 (S1) 13.80 14.14 13.52 13.64 12.79
Support 2 (S2) 13.24 13.79 13.16 12.67
Support 3 (S3) 12.34 13.24 12.55
Support 4 (S4) 12.18